29 MAR 2024 Pharmaceuticals Submission of an Application for the First Hematological Malignancies Gene Panel Test in Japan
22 NOV 2023 Pharmaceuticals Otsuka's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collaboration - AstraZeneca's Truqap™ for the treatment of metastatic breast cancer approved in the U.S.
19 SEP 2023 Pharmaceuticals Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
10 NOV 2022 Pharmaceuticals Announcement of Termination of Co-Development and Exclusive MarketingAgreements with Takara Bio for NY-ESO-1・siTCR® gene therapy candidate
22 AUG 2022 Pharmaceuticals European Medicines Agency commences review of oral fixed-dosecombination of decitabine and cedazuridine for the treatment ofadults with acute myeloid leukemia
15 APR 2022 Pharmaceuticals Osaka University and Otsuka Pharmaceutical to Enter into an Exclusive License Agreement on New Anti-tumor Antibody
29 MAR 2022 Pharmaceuticals Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. ofRadioligand Therapy for Metastatic Castration-Resistant Prostate Cancer- Out-licensed by ABX in Germany, an indirectly-owned subsidiary of Otsuka Pharmaceutical -
16 DEC 2021 Pharmaceuticals Otsuka and Rebirthel Sign Licensing Agreement for iPSC-derived CAR-T / TCR-T Production Technology
9 NOV 2021 Pharmaceuticals Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted CAR Gene Therapies
25 AUG 2021 Pharmaceuticals Busulfex Injection 60mg Approved in Japan for Once-daily Administration in Pediatric Patients
15 OCT 2020 Pharmaceuticals Otsuka and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitabine in patients with previously treated AML and MDS/CMML
8 JUL 2020 Pharmaceuticals Otsuka announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI®, an oral hypomethylating agent (HMA) therapy for MDS and CMML
24 JUN 2020 Pharmaceuticals Clinical program for NY-ESO-1/siTCRTM gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine
25 MAR 2020 Pharmaceuticals Otsuka's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
7 JUN 2019 Pharmaceuticals Otsuka and Taiho Announce that Taiho Will Commercialize Two of Astex Pharmaceuticals' Drug Candidates in North America
7 JUN 2019 Pharmaceuticals Otsuka and its Subsidiary Astex Pharmaceuticals, Inc. Announce Positive Results from a Phase III Clinical Trial of Anticancer Candidate ASTX727
14 FEB 2019 Pharmaceuticals Designation Description Change of NY-ESO-1・siTCRTM gene therapy product under "SAKIGAKE Designation System"
25 SEP 2018 Pharmaceuticals Busulfex Injection 60mg Approved in Japan for Once-Daily Administration in Adults
31 JUL 2018 Pharmaceuticals Otsuka and Astex announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy
9 APR 2018 Pharmaceuticals Otsuka enters agreement with Takara Bio for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies
25 DEC 2017 Pharmaceuticals Otsuka to Invest in Megakaryon Corporation, with the Aim to Advance Commercialization of iPS-cell-derived Platelet Preparations
23 MAR 2017 Pharmaceuticals Ribociclib (LEE011) Receives Regulatory Approval in U.S. as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitor
15 DEC 2016 Pharmaceuticals Otsuka Signs Japan-Exclusive License Agreement with Takara Bio for the Investigational Cancer Treatment HF10, an Oncolytic Virus
18 NOV 2016 Pharmaceuticals ICLUSIG® Tablets 15 mg Now Available in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
19 OCT 2016 Pharmaceuticals Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collaboration with Otsuka's Subsidiary Astex Pharmaceuticals
28 SEP 2016 Pharmaceuticals ICLUSIG® Tablets 15 mg Approved in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
20 APR 2016 Pharmaceuticals Otsuka's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia
8 JAN 2016 Pharmaceuticals Otsuka and ARIAD Announce New Drug Application for Ponatinib Submitted in Japan for the Treatment of Refractory Leukemia
29 JUL 2015 Pharmaceuticals Otsuka Pharmaceutical's Subsidiary Astex Enters New Consortium for Drug Discovery Research at the University of Cambridge
31 MAR 2014 Pharmaceuticals Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen® From Eisai (U.S.)
14 SEP 2012 Pharmaceuticals Kyowa Hakko Kirin Returns to Otsuka Pharmaceutical the Rights to Develop and Market Busulfex®, for Use As a Part of Conditioning Regimen Prior to Hematopoietic Progenitor Cell Transplantation, in Japan and in Asian Countries & Regions
29 JUN 2012 Pharmaceuticals Otsuka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
16 JUN 2011 Pharmaceuticals Anti-cancer agent "Sprycel® 20mg Tablets and Sprycel® 50mg Tablets (dasatinib)" approved as the first-line treatment of chronic myeloid leukemia-A new treatment option for newly-diagnosed CML patients-
13 JUN 2011 Pharmaceuticals Otsuka Announces Initiation of Phase I Clinical Trial for Therapeutic Cancer Vaccine OCV-105
1 FEB 2011 Pharmaceuticals Otsuka Announces Initiation of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101
21 DEC 2010 Pharmaceuticals Starting co-promotion of the anti-cancer agent SPRYCEL® Tablet 20mg and SPRYCEL® Tablet 50mg (dasatinib) in Japan
17 DEC 2010 Pharmaceuticals The results of a subset analysis of Japanese patients from the DASISION trial comparing SPRYCEL® (dasatinib) with imatinib in the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.
7 DEC 2010 Pharmaceuticals Follow-Up Results from Study Comparing SPRYCEL® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data*1
1 NOV 2010 Pharmaceuticals FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase
4 OCT 2010 Pharmaceuticals OTSUKA OPENS FIRST OFFICE IN CANADA Important Milestone for Growing North American Pharmaceutical Operations
12 JUL 2010 Pharmaceuticals SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
30 JUN 2010 Pharmaceuticals GW and Otsuka Agree Three Year Extension to Global Cannabinoid Research Collaboration
9 JUN 2010 Pharmaceuticals Four-Year Follow-Up Data for SPRYCEL® (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®*
8 JUN 2010 Pharmaceuticals SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
26 JAN 2010 Pharmaceuticals Otsuka Pharmaceutical Co., Ltd. and Fuso Pharmaceutical Industries, Ltd. Conclude Agreement for the Manufacturing and Commercialization of Therapeutic Cancer Vaccine, OTS102
6 APR 2009 Pharmaceuticals Otsuka and Bristol-Myers Squibb Extend U.S. Agreement for ABILIFY and Establish a Global Oncology Collaboration